Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients

Year 2022, Volume: 4 Issue: 3, 14 - 20, 03.01.2023

Mehmet Ali Gül , Nezahat Kurt , Mustafa Çapraz , Alpaslan Öztürk

https://doi.org/10.55895/sshs.1213382

Abstract

The 2019 coronavirus disease (COVID-19) has caused millions of cases worldwide. As the pandemic progresses, understanding the effects of this disease remains important. We aimed to examine the hematological effects of the disease. The research was carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. While PT and INR were found to significantly higher in patients using favipiravir (p<0.05), the elevation in aPTT values was not significant. As a consequence, it was obtained that favipiravir prolongs the clotting time. In the light of these results, it is recommended to consider this in anticoagulant therapy used for treatment.

Keywords

COVID-19, favipiravir, INR, PT, aPTT

References

• Ciaccio, M., & Agnello, L. (2020). Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagnosis (Berl), 7(4), 365-372. doi:10.1515/dx-2020-0057
• Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23), 2033-2040. doi:10.1182/blood.2020006000
• Conway, E. M., Mackman, N., Warren, R. Q., Wolberg, A. S., Mosnier, L. O., Campbell, R. A., . . . Morrissey, J. H. (2022). Understanding COVID-19-associated coagulopathy. Nat Rev Immunol, 22(10), 639-649. doi:10.1038/s41577-022-00762-9
• Mir, S. M., Tahamtan, A., Nikoo, H. R., Arabi, M. S., Moradi, A. W., Ardakanian, S., & Tabarraei, A. (2022). Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective study. Gene Rep, 26, 101448. doi:10.1016/j.genrep.2021.101448
• Thachil, J. (2020). What do monitoring platelet counts in COVID-19 teach us? Journal of Thrombosis and Haemostasis, 18(8), 2071-2072. doi:10.1111/jth.14879
• Tuğçe Atcali , S. Y., Cüneyt Çağlayan , Aykut Ulucan , Adem Kara. (2021). Effects of favipiravir on hematologic parameters and bone marrow in the rats. J Exp Clin Med, 39(1), 156-159.
• Yaylaci, S., Dheir, H., Senocak, D., Genc, A. B., Kocayigit, H., Cekic, D., . . . Karabay, O. (2020). The effects of favipiravir on hematological parameters of covid-19 patients. Rev Assoc Med Bras (1992), 66Suppl 2(Suppl 2), 65-70. doi:10.1590/1806-9282.66.S2.65 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229), 1054-1062. doi:10.1016/S0140-6736(20)30566-3